Genetic variants in C5 and poor response to eculizumab

New England Journal of Medicine

Volumn 370, Issue 7, 2014, Pages 632-639

  Nishimura, Jun Ichi ^a   Yamamoto, Masaki ^a   Hayashi, Shin ^c   Ohyashiki, Kazuma ^d   Ando, Kiyoshi ^f   Brodsky, Andres L ⁿ   Noji, Hideyoshi ^g   Kitamura, Kunio ^h   Eto, Tetsuya ⁱ   Takahashi, Toru ^j   Masuko, Masayoshi ^k   Matsumoto, Takuro ^l   Wano, Yuji ^m   Shichishima, Tsutomu ^g   Shibayama, Hirohiko ^a   Hase, Masakazu ^e   Li, Lan ^o   Johnson, Krista ^o   Lazarowski, Alberto ⁿ   Tamburini, Paul ^o   Inazawa, Johji ^c   Kinoshita, Taroh ^b   Kanakura, Yuzuru ^a   more..

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^d TOKYO MEDICAL UNIVERSITY   (Japan)

^e Alexion Pharma   (Japan)

^f TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^h Ichinomiya Municipal Hospital   (Japan)

ⁱ HAMANOMACHI HOSPITAL   (Japan)

^j Yamaguchi Grand Medical Center   (Japan)

^k NIIGATA UNIVERSITY MEDICAL AND DENTAL HOSPITAL   (Japan)

^l Takayama Red Cross Hospital   (Japan)

^m Iwate Prefectual Central Hospital   (Japan)

ⁿ UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^o ALEXION PHARMACEUTICALS   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C5; ECULIZUMAB; GENOMIC DNA; LACTATE DEHYDROGENASE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY N19 8; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANTIBODY COMBINING SITE; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; C5 GENE; CELL PROTECTION; CHINESE; CLINICAL ARTICLE; COMPLEMENT ACTIVATION; CONTROLLED STUDY; DNA POLYMORPHISM; DRUG BLOOD LEVEL; DRUG RESPONSE; EXON; GENE SEQUENCE; GENETIC SCREENING; GENETIC VARIABILITY; HAN CHINESE; HEMOLYSIS; HUMAN; IN VITRO STUDY; JAPANESE; LACTATE DEHYDROGENASE BLOOD LEVEL; MISSENSE MUTATION; NUCLEOTIDE SEQUENCE; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PRIORITY JOURNAL;

EID: 84893799889     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1311084     Document Type: Article

References (25)

1. Miyata T, Takeda J, Iida Y, et al. The cloning of PIG-A, a component in the early step of GPI-anchor biosynthesis. Science 1993;259:1318-20. (Pubitemid 23100269)
2. Takeda J, Miyata T, Kawagoe K, et al. Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria. Cell 1993;73:703-11. (Pubitemid 23159009)
3. Miyata T, Yamada N, Iida Y, et al. Abnormalities of PIG-A transcripts in granulocytes from patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med 1994;330:249-55. (Pubitemid 24034137)
4. Parker C, Omine M, Richards S, et al. Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood 2005;106:3699-709. (Pubitemid 41739003)
5. Brodsky RA. How I treat paroxysmal nocturnal hemoglobinuria. Blood 2009;113:6522-7.
6. Luzzatto L, Gianfaldoni G, Notaro R. Management of paroxysmal nocturnal haemoglobinuria: a personal view. Br J Haematol 2011;153:709-20.
7. Hillmen P, Lewis SM, Bessler M, Luzzatto L, Dacie JV. Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med 1995;333:1253-8.
8. Socié G, Mary JY, de Gramont A, et al. Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors. Lancet 1996;348:573-7. (Pubitemid 26283888)
9. Nishimura J, Kanakura Y, Ware RE, et al. Clinical course and flow cytometric analysis of paroxysmal nocturnal hemoglobinuria in the United States and Japan. Medicine (Baltimore) 2004;83:193-207. (Pubitemid 38649949)
10. Rother RP, Rollins SA, Mojcik CF, Brodsky RA, Bell L. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol 2007;25:1256-64. [Erratum, Nat Biotechnol 2007;25:1488.] (Pubitemid 350076509)
11. Parker C. Eculizumab for paroxysmal nocturnal haemoglobinuria. Lancet 2009;373:759-67.
12. Hillmen P, Hall C, Marsh JC, et al. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med 2004;350:552-9. (Pubitemid 38160785)
13. Hill A, Hillmen P, Richards SJ, et al. Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria. Blood 2005;106:2559-65. (Pubitemid 41510834)
14. Hillmen P, Young NS, Schubert J, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 2006;355:1233-43. (Pubitemid 44427447)
15. Hillmen P, Muus P, Dührsen U, et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood 2007;110:4123-8. (Pubitemid 350248472)
16. Brodsky RA, Young NS, Antonioli E, et al. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood 2008;111:1840-7. (Pubitemid 351451491)
17. Kanakura Y, Ohyashiki K, Shichishima T, et al. Safety and efficacy of the terminal complement inhibitor eculizumab in Japanese patients with paroxysmal nocturnal hemoglobinuria: the AEGIS clinical trial. Int J Hematol 2011;93:36-46.
18. Risitano AM, Notaro R, Marando L, et al. Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab. Blood 2009;113:4094-100.
19. Würzner R, Schulze M, Happe L, et al. Inhibition of terminal complement complex formation and cell lysis by monoclonal antibodies. Complement Inflamm 1991;8:328-40.
20. van den Berg CW. Purification of complement components, regulators, and receptors by classical methods. Methods Mol Biol 2000;150:15-52.
21. Zuber J, Fakhouri F, Roumenina LT, Loirat C, Frémeaux-Bacchi V. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol 2012;8:643-57.
22. Laursen NS, Andersen KR, Braren I, Spillner E, Sottrup-Jensen L, Andersen GR. Substrate recognition by complement convertases revealed in the C5-cobra venom factor complex. EMBO J 2011;30:606-16.
23. Wu J, Edberg JC, Redecha PB, et al. A novel polymorphism of FcgammaRIIIa (CD16) alters receptor function and predisposes to autoimmune disease. J Clin Invest 1997;100:1059-70. (Pubitemid 27386289)
24. Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002;99:754-8. (Pubitemid 34525533)
25. Treon SP, Hansen M, Branagan AR, et al. Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenström's macroglobulinemia. J Clin Oncol 2005;23:474-81. (Pubitemid 46224224)